Table 3 Procedure characteristics
|  | Intracoronary pro-UK No. (%) of patients (n = 89) | Intracoronary pro-UK combined with pre-dilatation No. (%) of patients (n = 90) | P Value |
|---|---|---|---|
Acute therapy following the first medical contact, No./total (%) | |||
 Loading dose of aspirin, 300 mg | 89 (100) | 90 (100) | 0.977 |
 Loading dose of ticagrelor, 180 mg | 89 (100) | 90 (100) | 0.977 |
 Inhaled oxygen | 74 (83.2) | 77 (85.6) | 0.893 |
 Percutaneous morphine | 9 (10.1) | 10 (11.1) | 0.615 |
Artery access | |||
 Right radial artery | 79 (88.8) | 77 (85.6) | 0.733 |
 Left radial artery | 3 (3.4) | 5 (5.6) | 0.524 |
 Right femoral artery | 7 (7.9) | 8 (8.9) | 0.658 |
Coronary artery disease | |||
 Single vessel disease | 27 (30.3) | 31 (34.5) | 0.588 |
 Multivessel disease | 62 (69.7) | 59 (65.6) | 0.636 |
Intracoronary pro-urokinase, No./total (%) | |||
 20 mg according to protocol | 89 (100) | 90 (100) | 0.977 |
 Duration of infusion, mean (SD), min | 3.4 (1.9) | 3.6 (1.6) | 0.856 |
Stent implantation | |||
 PCI with stent implant | 87 (99.3) | 88 (98.5) | 0.922 |
 Total No. of stents deployed, mean (SD) | 2.14 (1.1) | 2.27 (1.1) | 0.848 |
 Total length of stents deployed, mean (SD), mm | 29.52 (11.7) | 31.73 (10.6) | 0.632 |
 Poststent dilatation | 11 (12.4) | 13 (14.4) | 0.509 |
 Intravenous glycoprotein IIb/IIIa antagonist after PCI | 81 (91.1) | 83 (92.2) | 0.724 |